BRPI0920465A2 - metodo de tratamento de encefalopatia hepática - Google Patents
metodo de tratamento de encefalopatia hepáticaInfo
- Publication number
- BRPI0920465A2 BRPI0920465A2 BRPI0920465-2A BRPI0920465A BRPI0920465A2 BR PI0920465 A2 BRPI0920465 A2 BR PI0920465A2 BR PI0920465 A BRPI0920465 A BR PI0920465A BR PI0920465 A2 BRPI0920465 A2 BR PI0920465A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment method
- hepatic encephalopathy
- encephalopathy treatment
- hepatic
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10234908P | 2008-10-02 | 2008-10-02 | |
| US61/102349 | 2008-10-02 | ||
| PCT/US2009/059321 WO2010040020A1 (en) | 2008-10-02 | 2009-10-02 | Methods of treating hepatic encephalopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0920465A2 true BRPI0920465A2 (pt) | 2018-03-20 |
Family
ID=42073897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920465-2A BRPI0920465A2 (pt) | 2008-10-02 | 2009-10-02 | metodo de tratamento de encefalopatia hepática |
Country Status (21)
| Country | Link |
|---|---|
| US (12) | US20100204173A1 (pt) |
| EP (4) | EP3628319B1 (pt) |
| JP (2) | JP6037615B2 (pt) |
| CN (1) | CN102245615A (pt) |
| AU (1) | AU2009298389C1 (pt) |
| BR (1) | BRPI0920465A2 (pt) |
| CA (1) | CA2739436C (pt) |
| CY (1) | CY1122806T1 (pt) |
| DK (2) | DK2350096T3 (pt) |
| ES (2) | ES2770308T3 (pt) |
| FI (1) | FI3628319T3 (pt) |
| HR (2) | HRP20200284T1 (pt) |
| HU (2) | HUE048293T2 (pt) |
| IL (1) | IL212055A0 (pt) |
| LT (2) | LT2350096T (pt) |
| MX (2) | MX364102B (pt) |
| PL (2) | PL2350096T3 (pt) |
| PT (2) | PT2350096T (pt) |
| SI (2) | SI3628319T1 (pt) |
| SM (2) | SMT202400116T1 (pt) |
| WO (1) | WO2010040020A1 (pt) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| BRPI0920465A2 (pt) | 2008-10-02 | 2018-03-20 | Salix Pharmaceuticals, Inc. | metodo de tratamento de encefalopatia hepática |
| US12285414B2 (en) | 2008-10-02 | 2025-04-29 | Salix Pharmaceuticals, Inc. | Methods of treating hepatic encephalopathy |
| US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| KR20190099100A (ko) * | 2009-06-02 | 2019-08-23 | 샐릭스 파마슈티컬스 리미티드 | 간성 뇌병증의 치료방법 |
| MX2011013427A (es) * | 2009-06-15 | 2012-04-20 | Salix Pharmaceuticals Ltd | Modulacion de exposicion sistemica a rifaximina. |
| EP2493471B1 (en) | 2009-10-26 | 2019-11-27 | Thomas Julius Borody | Novel enteric combination therapy |
| CA2807242C (en) | 2010-08-04 | 2017-05-02 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| WO2012076832A1 (en) * | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
| BR112013022927A2 (pt) | 2011-03-09 | 2016-12-06 | Univ Minnesota | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição |
| US20130184302A1 (en) | 2011-11-02 | 2013-07-18 | Enoch Bortey | Methods for treating irritable bowel syndrome (ibs) and infections |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| ITBO20120368A1 (it) * | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| JP2015528507A (ja) * | 2012-09-13 | 2015-09-28 | サリックス ファーマスーティカルズ,インコーポレーテッド | 肝性脳症を患う対象の長期生存を改善し、再入院率を低減する方法 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US20150335615A1 (en) * | 2013-01-04 | 2015-11-26 | Toshihisa Kawai | Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| WO2014159609A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Peanut formulations and uses thereof |
| EP2991649B1 (en) * | 2013-04-30 | 2020-06-03 | Thomas Julius Borody | Compositions for treating obsessive-compulsive disorder |
| CN103340856A (zh) * | 2013-07-09 | 2013-10-09 | 荣港生技医药科技(北京)有限公司 | 一种利福昔明药物组合物及其制备方法 |
| CN106163528A (zh) | 2014-01-29 | 2016-11-23 | 梅克芳识别有限公司 | 用于治疗肝脑病的甾族化合物 |
| EP2927235B1 (en) | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
| AU2015260837B2 (en) | 2014-05-12 | 2019-02-28 | Alfasigma S.P.A. | New solvated crystal form of rifaximin, production, compositions and uses thereof |
| MX381919B (es) * | 2014-06-30 | 2025-03-13 | Salix Pharmaceuticals Inc | Métodos para repetir tratamiento de síndrome del intestino irritable (ibs). |
| TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
| CN114159476A (zh) | 2015-05-14 | 2022-03-11 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| CN114366759A (zh) | 2015-05-22 | 2022-04-19 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
| US20190000866A1 (en) * | 2016-01-08 | 2019-01-03 | Colonaryconcepts Llc | Food based delivery of therapeutic agent for treatment of hepatic encephalopathy |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| CA3038312A1 (en) | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| CN106822125A (zh) * | 2017-02-28 | 2017-06-13 | 丹诺医药(苏州)有限公司 | 一种利福霉素‑喹嗪酮双靶标分子的新用途 |
| CN106822119A (zh) * | 2017-02-28 | 2017-06-13 | 丹诺医药(苏州)有限公司 | 一种利福霉素‑硝基咪唑偶联分子的新用途 |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| EP3606541A1 (en) | 2017-04-05 | 2020-02-12 | Crestovo Holdings LLC | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| CN110996917A (zh) | 2017-05-26 | 2020-04-10 | 克雷斯顿沃控股公司 | 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法 |
| KR20200038506A (ko) | 2017-08-07 | 2020-04-13 | 핀치 테라퓨틱스, 인코포레이티드 | 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법 |
| EP4431094A3 (en) | 2017-11-10 | 2024-11-20 | Cosmo Technologies Ltd. | Oral rifamycin sv compositions |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| US12433945B2 (en) | 2018-08-16 | 2025-10-07 | Société des Produits Nestlé S.A. | Peanut oral immunotherapy with maintenance dose |
| CN113164527A (zh) | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
| CA3123605A1 (en) | 2018-12-20 | 2020-06-25 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy dosing schedule for missed doses |
| CA3137295A1 (en) | 2019-05-10 | 2020-11-19 | Aimmune Therapeutics, Inc. | Methods for improving the quality of life of a patient with a peanut allergy |
| CA3142214A1 (en) * | 2019-06-03 | 2020-12-10 | Bausch Health Ireland Limited | Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders |
| WO2021016081A1 (en) | 2019-07-19 | 2021-01-28 | Finch Therapeutics Holdings Llc. | Methods and products for treatment of gastrointestinal disorders |
| CN115715193A (zh) * | 2020-03-24 | 2023-02-24 | 博士医疗爱尔兰有限公司 | 用于治疗显性肝性脑病的利福昔明的固体分散体 |
| CA3184054A1 (en) | 2020-06-26 | 2021-12-30 | Jacob Cole | Targeted release rifaximin compositions |
| US20250345400A1 (en) * | 2022-05-18 | 2025-11-13 | Virginia Commonwealth University | Methods for treatment of cognitive impairment in cirrhosis patients |
| EP4780450A1 (en) * | 2023-09-19 | 2026-07-29 | The United States Government as represented by the Department of Veterans Affairs | Rifamycin composition for treating sarcopenia |
| WO2025157240A1 (zh) * | 2024-01-26 | 2025-07-31 | 丹诺医药(苏州)股份有限公司 | 化合物用于制备治疗细菌代谢相关疾病的药物的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132910A (en) | 1962-03-26 | 1964-05-12 | Eastman Kodak Co | Cabinetry structure |
| US3132908A (en) | 1962-04-02 | 1964-05-12 | Carrier Corp | Thrust bearing construction |
| IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| US4343785A (en) | 1981-08-10 | 1982-08-10 | Basf Wyandotte Corporation | Gel dentifrice compositions |
| IT1199374B (it) * | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
| ES2114502B1 (es) | 1996-07-29 | 1999-07-01 | Univ Santiago Compostela | Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas. |
| WO1998010649A1 (en) | 1996-09-13 | 1998-03-19 | University Technology Corporation | Biocompatible cationic detergents and uses therefor |
| IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| US20020028764A1 (en) | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| US20040229948A1 (en) * | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
| US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
| ATE448775T1 (de) * | 2002-08-29 | 2009-12-15 | Activbiotics Pharma Llc | Rifalazil zur behandlung von infektionen mit clostridium difficile |
| TW200418485A (en) * | 2002-09-23 | 2004-10-01 | Activbiotics Inc | Rifalazil compositions and therapeutic regimens |
| US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
| US7256202B2 (en) | 2003-12-31 | 2007-08-14 | Halow George M | Composition and method for treatment of hepatic encephalopathy |
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| US8003118B2 (en) * | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| US20090233888A1 (en) | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
| MX2008011305A (es) | 2006-03-09 | 2009-02-10 | Salix Pharmaceuticals Inc | Preparacion anti-disfunsion rectal con rifaximina. |
| CA2671197A1 (en) | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
| MX2009001342A (es) | 2006-08-02 | 2009-08-31 | Salix Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion. |
| CN101534840A (zh) | 2006-08-02 | 2009-09-16 | 萨利克斯药品公司 | 治疗放射性肠炎的方法 |
| EP2069363B1 (en) | 2006-09-22 | 2013-03-20 | Cipla Ltd. | Rifaximin in an amorphous form |
| US20100136125A1 (en) | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
| ES2798253T3 (es) | 2007-07-06 | 2020-12-10 | Lupin Ltd | Composiciones farmacéuticas de rifaximina |
| JP5755878B2 (ja) * | 2007-07-06 | 2015-07-29 | ルパン リミテッドLupin Limited | リファキシミンの薬剤組成物 |
| US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| US8067429B2 (en) | 2008-02-25 | 2011-11-29 | Salix Pharmaceuticals, Ltd. | Forms of rifaximin and uses thereof |
| PT2252148T (pt) * | 2008-02-26 | 2020-01-23 | Salix Pharmaceuticals Ltd | Métodos de tratamento da síndrome do intestino irritável |
| US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| US20100317681A1 (en) | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
| BRPI0920465A2 (pt) * | 2008-10-02 | 2018-03-20 | Salix Pharmaceuticals, Inc. | metodo de tratamento de encefalopatia hepática |
| US12285414B2 (en) | 2008-10-02 | 2025-04-29 | Salix Pharmaceuticals, Inc. | Methods of treating hepatic encephalopathy |
| KR20190099100A (ko) * | 2009-06-02 | 2019-08-23 | 샐릭스 파마슈티컬스 리미티드 | 간성 뇌병증의 치료방법 |
| DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
| EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
| US20130289056A1 (en) | 2010-08-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Methods of administering an egfr inhibitor |
| KR20130027255A (ko) * | 2011-09-07 | 2013-03-15 | 삼성전자주식회사 | 키 조립체 및 이를 구비한 회전식 입력 장치 |
| MX367640B (es) | 2011-11-30 | 2019-08-29 | Astrazeneca Ab | Tratamiento combinado del cáncer. |
| CN106462181B (zh) | 2014-04-29 | 2019-10-25 | 惠普发展公司,有限责任合伙企业 | 用于计算装置的铰接组件 |
| US20160191956A1 (en) * | 2014-12-15 | 2016-06-30 | Cable Television Laboratories, Inc. | Software defined networking in a cable tv system |
| MX376083B (es) | 2015-06-04 | 2025-03-07 | Pfizer | Formas de dosificacion solidas de palbociclib. |
-
2009
- 2009-10-02 BR BRPI0920465-2A patent/BRPI0920465A2/pt not_active Application Discontinuation
- 2009-10-02 AU AU2009298389A patent/AU2009298389C1/en active Active
- 2009-10-02 HU HUE09818544A patent/HUE048293T2/hu unknown
- 2009-10-02 ES ES09818544T patent/ES2770308T3/es active Active
- 2009-10-02 EP EP19207534.9A patent/EP3628319B1/en active Active
- 2009-10-02 SI SI200932192T patent/SI3628319T1/sl unknown
- 2009-10-02 SM SM20240116T patent/SMT202400116T1/it unknown
- 2009-10-02 CN CN2009801490791A patent/CN102245615A/zh active Pending
- 2009-10-02 PL PL09818544T patent/PL2350096T3/pl unknown
- 2009-10-02 SM SM20200124T patent/SMT202000124T1/it unknown
- 2009-10-02 JP JP2011530261A patent/JP6037615B2/ja active Active
- 2009-10-02 HR HRP20200284TT patent/HRP20200284T1/hr unknown
- 2009-10-02 SI SI200932045T patent/SI2350096T1/sl unknown
- 2009-10-02 ES ES19207534T patent/ES2972135T3/es active Active
- 2009-10-02 EP EP25177992.2A patent/EP4591862A3/en active Pending
- 2009-10-02 HR HRP20240317TT patent/HRP20240317T1/hr unknown
- 2009-10-02 EP EP09818544.0A patent/EP2350096B1/en not_active Revoked
- 2009-10-02 DK DK09818544.0T patent/DK2350096T3/da active
- 2009-10-02 DK DK19207534.9T patent/DK3628319T3/da active
- 2009-10-02 PT PT98185440T patent/PT2350096T/pt unknown
- 2009-10-02 LT LTEP09818544.0T patent/LT2350096T/lt unknown
- 2009-10-02 HU HUE19207534A patent/HUE065491T2/hu unknown
- 2009-10-02 PL PL19207534.9T patent/PL3628319T3/pl unknown
- 2009-10-02 US US12/572,344 patent/US20100204173A1/en not_active Abandoned
- 2009-10-02 CA CA2739436A patent/CA2739436C/en active Active
- 2009-10-02 WO PCT/US2009/059321 patent/WO2010040020A1/en not_active Ceased
- 2009-10-02 MX MX2014013652A patent/MX364102B/es unknown
- 2009-10-02 FI FIEP19207534.9T patent/FI3628319T3/fi active
- 2009-10-02 EP EP24155114.2A patent/EP4342465A3/en active Pending
- 2009-10-02 LT LTEP19207534.9T patent/LT3628319T/lt unknown
- 2009-10-02 MX MX2011003548A patent/MX2011003548A/es active IP Right Grant
- 2009-10-02 PT PT192075349T patent/PT3628319T/pt unknown
-
2011
- 2011-03-31 US US13/077,373 patent/US20110243879A1/en not_active Abandoned
- 2011-03-31 IL IL212055A patent/IL212055A0/en active IP Right Grant
-
2013
- 2013-02-15 US US13/768,617 patent/US8969398B2/en active Active
-
2015
- 2015-02-03 US US14/612,697 patent/US9629829B2/en active Active
- 2015-05-21 JP JP2015103724A patent/JP2015166381A/ja active Pending
-
2017
- 2017-03-16 US US15/460,704 patent/US9949958B2/en active Active
-
2018
- 2018-03-15 US US15/922,010 patent/US10335397B2/en active Active
-
2019
- 2019-05-16 US US16/414,018 patent/US10709694B2/en active Active
-
2020
- 2020-02-21 CY CY20201100167T patent/CY1122806T1/el unknown
- 2020-06-05 US US16/893,651 patent/US20200368213A1/en not_active Abandoned
-
2021
- 2021-03-26 US US17/213,678 patent/US11633384B2/en active Active
-
2023
- 2023-03-06 US US18/117,899 patent/US20240066010A1/en not_active Abandoned
- 2023-04-18 US US18/135,823 patent/US20230330071A1/en not_active Abandoned
-
2024
- 2024-05-17 US US18/667,886 patent/US12697326B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2350096T (pt) | Métodos de tratamento da encefalopatia hepática | |
| BRPI0910854A2 (pt) | métodos de tratamento | |
| BRPI0910259A2 (pt) | métodos de tratamento de inflamação | |
| BRPI0917575A2 (pt) | métodos de tratamento de talassemia | |
| BRPI0919116A2 (pt) | método | |
| EP2376493A4 (en) | DIHYDROPYRIMIDOPYRIMIDINDERIVAT | |
| BRPI0919426A2 (pt) | métodos melhorado de exposição de rna | |
| BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
| BRPI0922480A2 (pt) | compósitos de nanocalcita | |
| EP2380877A4 (en) | PYRIDINE-3-CARBONSÄUREAMIDDERIVAT | |
| PT3056224T (pt) | Método de esterilização | |
| BRPI0906764A2 (pt) | Processos | |
| PT2361116T (pt) | Aparelho de irradiação | |
| BRPI0914841A2 (pt) | aparelho de massagem | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| EP2336132A4 (en) | MORPHOLINPURINDERIVAT | |
| DK2313489T3 (da) | Fremstillingsmetode | |
| BRPI0919127A2 (pt) | métodos para tratamento de água | |
| DK2244628T3 (da) | Patientdata-sensorapparat | |
| BRPI0922652A2 (pt) | Derivados de quinazolinamida | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
| BRPI0916597A2 (pt) | Método | |
| HRP20160577T1 (hr) | Liječenje osteoartritisa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 498/00 , A61K 31/44 , A01N 43/42 Ipc: A61K 31/08 (2006.01), C07D 498/00 (2006.01), A61K |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |